Get started
VolitionRX LimitedVolitionRX LimitedVolitionRX Limited

VolitionRX Limited

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

VNRX trade ideas

VolitionRX | VNRX | Long at $0.54***Stay away if you are risk averse (small cap with 300-400k daily volume and could go to $0). VolitionRX AMEX:VNRX is a U.S.-based, multinational epigenetics company focused on developing blood tests for early disease detection, primarily targeting cancer and sepsis. Its Nu.Q blood tests are primarily for humans, focusing on early detection of diseases like cancer and sepsis. However, the company has also explored veterinary applications through its Nu.Q Vet product line, targeting cancer screening in animals, particularly dogs. Recent insider purchases got my attention, with the CEO and Director each grabbing $100k worth at $0.55. Plus, many other insiders have recently been awarded options. The company is making progress in signing multiple licensing deals for their Nu.Q platform in the human market, with strong interest from large companies. Many development milestones have been made within their cancer testing program and more are likely to be announced. However, the company is unprofitable at this time, and this is a highly risky / speculative play. It may take years to unfold or be a total disaster and go to $0.00. Rolling the dice at $0.54 with the goal to reach $0.75 and $1.00 in the coming 1-2 years. Analyst targets are in the $3.00-$3.50 range.
AMEX:VNRXLong
by WorthlessViews
$VNRX Prepping For A Breakout$VNRX has popped on our radar. $VNRX is trading above its 20, 50, and 200 day moving averages. A breakout to new highs above $3.63 sets $VNRX up for a nice move. Yesterday, the company put out some news. AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platform to China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, the parties have commenced a clinical study in China in lung cancer. Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, commented: "We are happy to have executed this agreement with Fosun Long March and are delighted that the clinical study is already underway and expected to be completed by the end of this year." Dr. Yuejian Zhang, Chairman of Fosun Long March, remarked: "We were impressed with Volition's preliminary data, particularly in lung cancer, and are happy to have started work on these initial clinical studies. Whilst China represents a little under 20% of the world's population, it accounted for almost 24% of cancer diagnoses and 30% of cancer-related deaths worldwide in 2018, almost a third of which were due to lung cancer and colorectal cancer. We look forward to completing this important study and working together with Volition to launch Nu.Q in China." "The need for a simple, easy to use, cost effective test for cancer is truly universal and we hope very much that our Nu.Q tests can help revolutionize the way cancer is diagnosed worldwide," commented Cameron Reynolds, Chief Executive Officer of Volition. "We see Asia, and particularly lung cancer in China, as a key market for Volition. We are excited about the commencement of our work in China and look forward to a successful collaboration with Fosun Long March." About Fosun Long March Established in 1989, Fosun Long March is the investment platform of in-vitro diagnostics division of Fosun Pharma Group and has since accelerated merger and acquisition of new products introduction into China. With its wide range of in-vitro diagnostics products, strength in manufacturing and strong nation-wide sales network, Fosun Long March is one of the most influential brands in in-vitro diagnostics in China. Fosun Long March's network and expertise will assist Volition with the facilitation and coordination of the collection, provision and testing of blood samples using Volition's proprietary Nu.Q(TM) assays for the clinical studies, with Fosun's hospitals, research institutions and clinics, as well as other third-party hospitals, universities, research institutions and clinics in China. About Volition Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics(TM), which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are currently centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
AMEX:VNRXLong
by OptionsGains
2